Navigation Links
Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
Date:7/22/2010

oducts under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 4, 2010 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cornerstone Therapeutics Announces Management Change
2. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
3. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
4. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
5. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
6. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
7. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
8. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
9. Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
10. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
11. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Decision Resources Group finds ... Memphis health system and hospital ... integration, with rivals Methodist Le Bonheur Healthcare and Baptist ... to coordinate patient care. In addition, a national contract ... most health plan enrollment in the Memphis ...
(Date:8/27/2014)... By now, if you haven,t heard about the ALS Ice ... awareness campaign has brought this devastating disease to the forefront ... Million (and counting) for ALS. Every day, more and more ... as well. One such company, Acorn Stairlifts Inc., ... works with ALS sufferers and helps to provide solutions for ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Heart Valve Repair and Replacement ... About Heart Valve Repair and Replacement ... which control the flow of blood during the ... diseases such as valvular stenosis, valvular insufficiency or ...
Breaking Medicine Technology:Memphis-area Health Systems Turn Attention to Clinical Integration 2Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
(Date:8/27/2014)... 27, 2014 BESLER Consulting , ... services for hospitals, is pleased to announce that it ... of America’s Fastest-Growing Companies. The list represents the most ... independent entrepreneurs. , "It's been an exciting year ... included in this year's Inc. 5000 list,” said Jonathan ...
(Date:8/27/2014)... designed to help regulate the blood,s iron supply shows promise ... to results from the first human study of ... , the Journal of the American Society of Hematology ... blood cells are in short supply or do not function ... get enough oxygen, since there are fewer red blood cells ...
(Date:8/27/2014)... State University,s Center for Leadership in Disability (CLD) ... Maternal and Child Health Bureau of the Health ... the Autism Plan for Georgia, aimed at improving ... disorder. , In preparing for this project, CLD ... key stakeholders from across Georgia. The resulting plan ...
(Date:8/27/2014)... Cash House 's contributions to Horizons ... upkeep of the shelter including new initiatives and a wide ... the lives of each youth who walk through their door. ... for youth ages 16-25. Not only does Horizons operate as ... for the youth who come through their doors. Horizons has ...
(Date:8/27/2014)... Houston, TX (PRWEB) August 27, 2014 ... The reality is that depression has a mortality ... those with bi-polar disorder is slightly less, though it's ... of roughly 7%. In order to properly treat ... schizophrenia, and bi-polar, medication must be taken as directed. ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Among America’s Fastest Growing Private Companies 2Health News:Drug represents first potential treatment for common anemia 2Health News:Cash House a Major Supporter of Horizons for Youth 2Health News:Cash House a Major Supporter of Horizons for Youth 3Health News:MedicationDiscountCard.com now Makes Brintellix and Mental Illness Medications More Affordable with Discount Cards 2
... Kingdom recently instituted guidelines banning physicians, white coats and ... of bacteria within hospitals due to the belief that ... new study published today in the Journal of ... there is no difference in contamination of long- and ...
... - In an international Phase III randomized study, ... rapamycin (mTOR), has shown to dramatically improve progression-free ... (pNET), according to researchers from The University of ... findings were published in the latest New England ...
... Maureen Salamon HealthDay Reporter , WEDNESDAY, Feb. ... more than doubled the progression-free survival time for patients ... two new studies. In separate phase 3 trials ... sunitinib extended the survival of participants with advanced pancreatic ...
... Feb. 9 (HealthDay News) -- About one in 10 ... after. Though typically harmless, some may need treatment because ... "There are several different types of birthmarks, so it ... considering any possible treatments," dermatologist Dr. Sheila Fallon Friedlander, ...
... the National Institutes of Health envisions scientists being able ... gaining new insights into multi-gene disorders in the next ... drug targets and the development of practical treatments for ... plan from the National Human Genome Research Institute (NHGRI). ...
... PARK, Md. -- Under our feet and ubiquitous, lowly soil ... change and population growth. But in the January-February issue of ... team of scientists say soil is an essential piece of ... it. Strategies for doing so include refocusing and boosting research, ...
Cached Medicine News:Health News:Long- and short-sleeved physician workwear receive same amount of bacterial and MRSA contamination 2Health News:Everolimus improves progression-free survival for patients with rare pancreatic cancer 2Health News:Everolimus improves progression-free survival for patients with rare pancreatic cancer 3Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 2Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 3Health News:Not All Birthmarks Harmless, Expert Says 2Health News:NHGRI charts course for the next phase of genomics research 2Health News:NHGRI charts course for the next phase of genomics research 3Health News:NHGRI charts course for the next phase of genomics research 4Health News:Soil science: Healing our planet's ills from the ground up 2
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Medicine Products: